JP2010509576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509576A5 JP2010509576A5 JP2009535559A JP2009535559A JP2010509576A5 JP 2010509576 A5 JP2010509576 A5 JP 2010509576A5 JP 2009535559 A JP2009535559 A JP 2009535559A JP 2009535559 A JP2009535559 A JP 2009535559A JP 2010509576 A5 JP2010509576 A5 JP 2010509576A5
- Authority
- JP
- Japan
- Prior art keywords
- risk stratification
- proavp
- neurophysin
- copeptin
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 238000013517 stratification Methods 0.000 claims 10
- 208000017667 Chronic Disease Diseases 0.000 claims 9
- 102400000060 Copeptin Human genes 0.000 claims 6
- 101800000115 Copeptin Proteins 0.000 claims 6
- 208000032376 Lung infection Diseases 0.000 claims 6
- 102000002710 Neurophysins Human genes 0.000 claims 6
- 108010018674 Neurophysins Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 5
- 108010064409 proAVP hormone Proteins 0.000 claims 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims 4
- 102100032752 C-reactive protein Human genes 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 238000004393 prognosis Methods 0.000 claims 3
- 108010048233 Procalcitonin Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000003748 differential diagnosis Methods 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 238000001050 pharmacotherapy Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053442A DE102006053442A1 (de) | 2006-11-12 | 2006-11-12 | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006053442.5 | 2006-11-12 | ||
| PCT/DE2007/002037 WO2008058517A2 (de) | 2006-11-12 | 2007-11-11 | Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000176A Division JP2013083664A (ja) | 2006-11-12 | 2013-01-04 | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509576A JP2010509576A (ja) | 2010-03-25 |
| JP2010509576A5 true JP2010509576A5 (https=) | 2010-11-25 |
| JP5340160B2 JP5340160B2 (ja) | 2013-11-13 |
Family
ID=39277664
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535559A Active JP5340160B2 (ja) | 2006-11-12 | 2007-11-11 | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 |
| JP2013000176A Pending JP2013083664A (ja) | 2006-11-12 | 2013-01-04 | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 |
| JP2015151852A Active JP6170101B2 (ja) | 2006-11-12 | 2015-07-31 | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000176A Pending JP2013083664A (ja) | 2006-11-12 | 2013-01-04 | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 |
| JP2015151852A Active JP6170101B2 (ja) | 2006-11-12 | 2015-07-31 | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8158368B2 (https=) |
| EP (2) | EP2378290B1 (https=) |
| JP (3) | JP5340160B2 (https=) |
| CN (2) | CN101563613A (https=) |
| AT (1) | ATE522814T1 (https=) |
| DE (1) | DE102006053442A1 (https=) |
| DK (1) | DK2378290T3 (https=) |
| ES (2) | ES2370071T3 (https=) |
| HK (1) | HK1215731A1 (https=) |
| WO (1) | WO2008058517A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| PL2084543T3 (pl) | 2006-10-26 | 2018-04-30 | B.R.A.H.M.S Gmbh | Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| US20120329666A1 (en) * | 2009-10-05 | 2012-12-27 | Duke University | Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use |
| EP2776064A4 (en) | 2011-11-11 | 2015-08-05 | Woomera Therapeutics | PROVASOPRESSINE ANTAGONISTS AND ITS USES |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| KR102511128B1 (ko) | 2022-03-31 | 2023-03-16 | (주)네오닉스 | 배터리팩 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| DE10027954A1 (de) | 1999-12-22 | 2001-06-28 | Dade Behring Marburg Gmbh | Humanes Procalcitonin, dessen Herstellung und Verwendung |
| DE50014159D1 (de) | 1999-12-22 | 2007-04-26 | Dade Behring Marburg Gmbh | Lösungen von humanem Procalcitonin |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| ATE491727T1 (de) * | 2002-07-16 | 2011-01-15 | Woomera Therapeutics Inc | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen |
| WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102004047968A1 (de) * | 2004-10-01 | 2006-04-06 | B.R.A.H.M.S Ag | Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen |
| GB0508863D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Peptide |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| JP4983525B2 (ja) * | 2007-10-11 | 2012-07-25 | 住友電装株式会社 | ワイヤハーネスのプロテクタ取付構造 |
| US9229013B2 (en) * | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
-
2006
- 2006-11-12 DE DE102006053442A patent/DE102006053442A1/de not_active Withdrawn
-
2007
- 2007-11-11 CN CNA2007800420148A patent/CN101563613A/zh active Pending
- 2007-11-11 US US12/514,524 patent/US8158368B2/en active Active
- 2007-11-11 WO PCT/DE2007/002037 patent/WO2008058517A2/de not_active Ceased
- 2007-11-11 DK DK11170807.9T patent/DK2378290T3/en active
- 2007-11-11 ES ES07846321T patent/ES2370071T3/es active Active
- 2007-11-11 AT AT07846321T patent/ATE522814T1/de active
- 2007-11-11 ES ES11170807.9T patent/ES2634137T3/es active Active
- 2007-11-11 EP EP11170807.9A patent/EP2378290B1/de active Active
- 2007-11-11 CN CN201510454116.7A patent/CN105092858A/zh active Pending
- 2007-11-11 EP EP07846321A patent/EP2089718B1/de active Active
- 2007-11-11 JP JP2009535559A patent/JP5340160B2/ja active Active
-
2012
- 2012-03-21 US US13/425,928 patent/US20120270245A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000176A patent/JP2013083664A/ja active Pending
-
2015
- 2015-07-31 JP JP2015151852A patent/JP6170101B2/ja active Active
-
2016
- 2016-03-30 HK HK16103639.3A patent/HK1215731A1/zh unknown
- 2016-06-13 US US15/180,797 patent/US10718783B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509576A5 (https=) | ||
| JP6170101B2 (ja) | プロバソプレシン、特にコペプチンもしくはニューロフィジンｉｉによる、気道および肺の感染および慢性疾患の診断および／または危険性の層化 | |
| Markovic et al. | IL 33 correlates with COVID-19 severity, radiographic and clinical finding | |
| CN101553733B (zh) | 与心功能不全相关的呼吸道和肺部感染或炎性疾病的诊断 | |
| KR20180118822A (ko) | 패혈증 예후의 예측 방법 | |
| Górska et al. | Comparative study of periostin expression in different respiratory samples in patients with asthma and chronic obstructive pulmonary disease | |
| JP2016006426A5 (https=) | ||
| Huang et al. | Markers of inflammation in the breath in paediatric inflammatory bowel disease | |
| El Amrousy et al. | Pulmonary function tests abnormalities in children with inflammatory bowel disease: is it common? | |
| Zagórska et al. | Nitric oxide, IL‐6 and IL‐13 are increased in the exhaled breath condensates of children with allergic rhinitis | |
| JP6250351B2 (ja) | 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー | |
| Refaat et al. | Diagnostic accuracy of inflammatory biomarkers in bronchoalveolar lavage from patients with ventilator-associated pneumonia | |
| El-dib et al. | Diagnostic and prognostic role of procalcitonin in CAP | |
| Antus et al. | Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome | |
| EP3662289A1 (en) | Diagnosis and risk stratification of fungal infections | |
| Secord et al. | Pediatric Emergency Visits for Asthma Drop Significantly with COVID19 School Closure | |
| Zeng et al. | Thymidine phosphorylase is increased in patients with infection and could be a prognostic marker for sepsis and disseminated intravascular coagulation | |
| RU2479258C1 (ru) | Способ диагностики инфекционно-воспалительного процесса органов дыхания у детей | |
| Zhang et al. | Sestrin2 Was Involved in Airway Remodeling in COPD: A Multi-level Research | |
| Xu et al. | Validation of a nomogram model for Plastic Bronchitis in Pediatric Mycoplasma pneumoniae Pneumonia | |
| CN120779027A (zh) | 抑瘤素m作为生物标志物在制备诊断铜绿假单胞菌感染性肺炎试剂盒中的应用 | |
| Amrousy et al. | Pulmonary Function Tests Abnormalities in Children With Inflammatory Bowel Disease: Is It Common? | |
| CN113151443A (zh) | 细胞因子联合分析作为精神分裂症标志物及其应用 | |
| JP2022188803A (ja) | 可溶型ｃｌｅｃ２を用いたウイルス性肺炎のリスク評価法 | |
| CN120652105A (zh) | 一种与快速进展型间质性肺病相关的蛋白、检测试剂盒及其应用 |